Get the Daily Brief
Latest Biotech News
Singapore’s PRECISE taps pharma majors: Asian genomics alliance
Precision Health Research, Singapore (PRECISE) formalized a precompetitive partnership with Alnylam, Bayer, Boehringer Ingelheim and Novo Nordisk to analyze data from PRECISE‑SG100K, a population...
Janux reports 30% response rate in early JANX007 prostate data
Janux Therapeutics disclosed a new data cut from its Phase 1 study of JANX007, a T‑cell engager for prostate cancer, showing a 30% objective response rate in the evaluated cohort. The company...
Protego raises $130M — gears up for pivotal AL amyloidosis trial
Protego Biopharma closed an oversubscribed $130 million financing to advance its first‑in‑class oral program for light‑chain (AL) amyloidosis into a potential pivotal study next year. The round...
Regeneron commits $150M... Tessera deal targets gene writing for AATD
Regeneron Pharmaceuticals and Tessera Therapeutics struck a collaboration valued at $150 million to develop and commercialize TSRA‑196, Tessera’s in‑vivo gene‑writing candidate for alpha‑1...
Belite’s Phase 3 win — tinlarebant clears primary endpoint in Stargardt
Belite Bio reported topline results from the global Phase 3 DRAGON trial showing that tinlarebant met the study’s primary endpoint in adolescents with Stargardt disease type 1 (STGD1). The company...
Generate:Biomedicines launches Phase 3 — TSLP antibody moves to registrational studies
Generate:Biomedicines announced the start of two large Phase 3 trials for its lead TSLP (thymic stromal lymphopoietin) antibody, marking a key clinical inflection for the AI‑driven biotech. The...
Circular Genomics closes $15M Series A — circRNA blood biomarker for Alzheimer’s
Circular Genomics raised $15 million in a Series A round led by Mountain Group Partners to advance a circular RNA (circRNA)‑based biomarker platform for early detection of Alzheimer’s disease. The...
Morphocell extends Series A with $50M — scales tissue‑engineered liver programs
Morphocell Technologies announced a $50 million Series A financing extension — a $10 million add‑on to its earlier $40 million close — led by Investissement Québec with participation from CDP...
Analysts initiate coverage on BillionToOne — banks set bullish price targets
JP Morgan, BTIG and Jefferies initiated analyst coverage on molecular diagnostics firm BillionToOne, assigning a range of ratings and price targets that reflect optimism about the company’s...
Ideaya wins IND clearance — IDE‑034 poised for first‑in‑human solid tumor study
Ideaya Biosciences received FDA IND clearance to begin a Phase I study of IDE‑034, a bispecific antibody‑drug conjugate targeting B7H3/PTK7 coupled to a TOP1 payload, in patients with advanced...
RNAi therapeutic shows functional‑cure promise for chronic hepatitis B
A study published in Nature Communications reports that a novel RNA interference (RNAi) therapeutic produced results consistent with a functional cure for chronic hepatitis B in preclinical and...
Regeneron bets $150M on Tessera’s gene writing: partnership signed
Regeneron struck a $150 million partnership with gene-writing startup Tessera Therapeutics to accelerate Tessera’s platform toward clinical testing. The deal expands Regeneron’s commitment to...
Protego raises $130M to advance oral amyloidosis candidate – pivotal trial planned
Protego Biopharma closed a $130 million financing to support a potential pivotal study of its oral small molecule for light chain (AL) amyloidosis. Investors behind the round include executives...
Generate:Biomedicines launches two Phase 3 trials for TSLP antibody – AI-designed drug advances
Generate:Biomedicines announced it is initiating two Phase 3 studies of its lead TSLP (thymic stromal lymphopoietin) antibody, marking a major clinical inflection for an AI‑driven biotech. The...
Belite wins Phase 3 for Stargardt drug – U.S. filing now in sight
Belite Bio reported a Phase 3 victory for tinlarebant in adolescents with Stargardt disease, meeting the trial’s primary endpoint and clearing a major regulatory hurdle. The result strengthens...
RNAi therapy shows functional‑cure potential for chronic hepatitis B in Nature Communications
Researchers reported a novel RNA interference (RNAi) therapeutic that produced results consistent with a functional cure for chronic hepatitis B (HBV) in preclinical and early clinical evaluation,...
Menin inhibitors advance as targeted therapy for KMT2A‑rearranged leukemia
New data spotlight menin inhibitors as a targeted therapeutic strategy for KMT2A‑rearranged acute leukemias, a genetically defined and aggressive subtype. Researchers and early‑stage developers...
Endpoints Signal launches; BPSI Q4 2025 reads 78 – biopharma mood stays dour
Endpoints News launched Endpoints Signal, an intelligence platform led by Tom Randall, and published the inaugural Biopharma Sentiment Index (BPSI) for Q4 2025. The BPSI scored 78—well below a...
FDA biosimilar plan collides with patent office policy – regulatory friction grows
The FDA proposed guidance to streamline biosimilar approvals—aiming to slash time and cost for copycat biologics—while critics say the U.S. Patent and Trademark Office’s tougher stance on inter...
Quantifying α‑synuclein seeds in CSF—new assay could change Parkinson’s trials
Researchers described an endpoint‑dilution seed amplification assay (SAA) that quantifies α‑synuclein seeds in cerebrospinal fluid with improved precision, enabling measurement of pathological...